NEWS

Bristol Myers Squibb has developed a 120-mg/12-mL vial. This vial is available in addition to the current vial sizes (40 mg, 100 mg, and 240 mg). For NDC codes and OPDIVO storage information, see the vial flashcard HERE. Please ensure the 120-mg vial is included in your EHR for prescribing. If you need help adding […]

Written by: Kelly Valla, PharmD, BCOP, Emory Healthcare Winship Cancer Institute DOWNLOAD HERE Description: The purpose of this PQI is to discuss the clinical considerations around the use of loncastuximab tesirine-lply (Zynlonta®) to optimize the outcomes for patients with relapsed/refractory large B-cell lymphoma. Background: Loncastuximab tesirine-lply is a CD19 directed antibody-drug conjugate with a pyrrolobenzodiazepine […]

Written by: Kirollos Hanna, PharmD, BCPS, BCOP, Mayo Clinic College of Medicine and M Health Fairview and Kayla Randle, PharmD, BCOP, Kaiser Permanente – Southwood Oncology Clinic Download Here Description: Brentuximab vedotin is a CD30-directed antibody drug conjugate (ADC) indicated as front-line treatment for patients with classical stage III/IV Hodgkin’s Lymphoma (cHL) or CD30-expressing peripheral […]

Written by: Katie Carter, PharmD, BCPS, Indiana University Health Download Here  Description: Olaparib is a poly ADP-ribose polymerase (PARP) enzyme inhibitor and is FDA approved as a targeted therapy for BRCA-mutated breast cancer, ovarian, pancreatic cancer, as well as prostate cancer.  This PQI will highlight its place in therapy in these disease states, safety profiles, and clinical pearls regarding […]

Written by: Anna Howard, PharmD, BCOP, Billings Clinic Download Here Description: The purpose of this PQI is to discuss the option of using liposomal daunorubicin-cytarabine for patients with newly diagnosed therapy-related Acute Myeloid Leukemia (AML) or AML with myelodysplasia-related changes (AML-MRC).1 Background: Liposomal daunorubicin-cytarabine is a combination of daunorubicin and cytarabine in a fixed molar […]

Written by: Jody Agena, PharmD, MBA, BCOPDownload Here Description: Ibrutinib is a small molecule that acts as a potent, irreversible inhibitor of Bruton’s Tyrosine Kinase (BTK), a key component of the B-cell receptor and cytokine receptor signaling pathway.  BTK inhibition is vital for decreased malignant B-cell proliferation and survival.  This molecule disrupts the proliferation of […]

Written by: Joshua Nubla, PharmD, NCODA Download Here Description: This PQI will discuss management strategies for oncolytic medication induced diarrhea including combinations of fluid hydration therapies, antimotility agents such as loperamide, and dose modifications. Background: A common side effect with many oncolytic therapies is medication induced diarrhea which can result from chemotherapy or targeted therapy […]

Written by: Brady Quinn, PharmD and Britny Rogala, PharmD, BCOP – University of Rhode Island College of Pharmacy Download Here Description of PQI: Discuss prevention and management strategies for treatment related constipation.   Background: The utilization of proper diet, over-the-counter medications, and alternative prescriptions can be helpful for patients suffering from multisource drug induced constipation. […]

Written by: Neal Dave, PharmD and Julianne Orr, PharmD Download Here Description of PQI:  Discuss the prevention and management of opioid induced constipation. Background: Constipation is a major side effect of opioid administration and should be assessed and managed by the healthcare team. In cancer patients receiving chronic opioid therapy, the prevalence of constipation can […]

Written By: Natasha Olson, PharmD, NCODA Download Here Description: The purpose of this PQI is to provide proper identification and management of patients who may benefit from the use of non-hormonal contraception using lactic acid/citric acid/potassium bitartrate (Phexxi), a novel non-hormonal, vaginal pH modulator. Background: Lactic acid/citric acid/potassium bitartrate is indicated for the prevention of […]

Written by: Kristyn DiSogra, PharmD, BCOP and Justin Arnall, PharmD, BCOP, Atrium Health Download Here Description: The purpose of this PQI is to highlight implementation of telehealth symptom and risk survey completion by pharmacists or other healthcare providers for myelofibrosis (MF) patients. The goal is to improve provider clinical care pathway adherence and treatment optimization […]

Written by: Jonas Congelli, RPh Hematology Oncology Associates of CNY Download Here Description: To discuss prevention and management of Hand-Foot Syndrome. Background: Palmar-plantar erythrodysesthesia, also known as hand-foot syndrome (HFS) is a widely recognized dose-limiting toxicity of certain chemotherapy agents. A comprehensive list can be found in the supplemental information section. Typically, HFS occurs within the […]